Cargando…

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling

Hypoxia-activated prodrugs are bioactivated in oxygen-deficient tumour regions and represent a novel strategy to exploit this pharmacological sanctuary for therapeutic gain. The approach relies on the selective metabolism of the prodrug under pathological hypoxia to generate active metabolites with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jackson-Patel, Victoria, Liu, Emily, Bull, Matthew R., Ashoorzadeh, Amir, Bogle, Gib, Wolfram, Anna, Hicks, Kevin O., Smaill, Jeff B., Patterson, Adam V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861431/ https://www.ncbi.nlm.nih.gov/pubmed/35211015 http://dx.doi.org/10.3389/fphar.2022.803602

Ejemplares similares

Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures
por: Hong, Cho R., et al.
Publicado: (2018)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach
por: Ball, Patrick, et al.
Publicado: (2023)

An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids
por: Mao, Xinjian, et al.
Publicado: (2018)

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)

Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications
por: Ashoorzadeh, Amir, et al.
Publicado: (2022)

Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
por: Dachs, Gabi U., et al.
Publicado: (2009)

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
por: Abbattista, Maria R., et al.
Publicado: (2021)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents
por: Omran, Ziad, et al.
Publicado: (2021)

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
por: Foehrenbacher, Annika, et al.
Publicado: (2013)

Use of physiological based pharmacokinetic modeling for cross-species prediction of pharmacokinetic and tissue distribution profiles of a novel niclosamide prodrug
por: Yang, Mengbi, et al.
Publicado: (2023)

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice
por: Gu, Yongchuan, et al.
Publicado: (2017)

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
por: Spiegelberg, Linda, et al.
Publicado: (2019)

On-Lattice Simulation of T Cell Motility, Chemotaxis, and Trafficking in the Lymph Node Paracortex
por: Bogle, Gib, et al.
Publicado: (2012)

Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models
por: Hong, Xiaodan, et al.
Publicado: (2022)

The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy
por: Green, Laura K., et al.
Publicado: (2013)

A virtual lymph node model to dissect the requirements for T-cell activation by synapses and kinapses
por: Moreau, Hélène D, et al.
Publicado: (2016)

Editorial: Prodrug design and therapeutic applications
por: Xiao, Qicai, et al.
Publicado: (2023)

Chinese medicinal herbs as potential prodrugs for obesity
por: Law, Siu Kan, et al.
Publicado: (2022)

First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects
por: Zhang, Hong, et al.
Publicado: (2022)

Pharmacokinetics of Acetaminophen and Metformin Hydrochloride in Rats After Exposure to Simulated High Altitude Hypoxia
por: Zhu, Jun-bo, et al.
Publicado: (2021)

Understanding the pharmacokinetics of prodrug and metabolite
por: Cho, Seungil, et al.
Publicado: (2018)

Glutathione S-conjugates as prodrugs to target drug-resistant tumors
por: Ramsay, Emma E., et al.
Publicado: (2014)

Expanding the toolbox of metabolically stable lipid prodrug strategies
por: Toti, Kiran S., et al.
Publicado: (2023)

Engineering the Escherichia coli Nitroreductase NfsA to Create a Flexible Enzyme-Prodrug Activation System
por: Sharrock, Abigail V., et al.
Publicado: (2021)

Synthesis, characterization and in vitro release performance of the pegylated valnemulin prodrug
por: DONG, Xinrui, et al.
Publicado: (2017)

Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs
por: Deng, Chaoyi, et al.
Publicado: (2022)

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates
por: Wang, Yanming, et al.
Publicado: (2022)

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug
por: Cheng, T L, et al.
Publicado: (1999)

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
por: Fu, Zhe, et al.
Publicado: (2021)

Esters of valerenic acid as potential prodrugs
por: Hintersteiner, Juliane, et al.
Publicado: (2014)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Rutin bioconjugates as potential nutraceutical prodrugs: An in vitro and in ovo toxicological screening
por: Dehelean, Cristina Adriana, et al.
Publicado: (2022)

Amplifying the efficacy of ALA-based prodrugs for photodynamic therapy using nanotechnology
por: Lou, Liang, et al.
Publicado: (2023)

Pseudomonas aeruginosa NfsB and nitro-CBI-DEI – a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy
por: Green, Laura K, et al.
Publicado: (2013)

Resveratrol activates CD8(+) T cells through IL-18 bystander activation in lung adenocarcinoma
por: Zhang, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5cqs2vsm3u92gev5oeeokjmfi6